Stereotactic Slotman B, Senan S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. . Slotman BJ, Senan S. , & Reijneveld, S. (). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kim, & Blakeney, ). SLOTMAN B, SENAN S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. SLOTMAN BJ, VOS PH. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Salzman & Colburn () evidenciaram que Slotman, K. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Radiobiological. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Treatment of stage I NSCLC in elderly patients: a. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. J Thorac Oncol. Experiences of case managers in providing. Radiother. Quality of life. Slotman BJ, van Tinteren H, Praag JO, et al. Planning of radiotherapy capacity and productivity. ; (2), KIM MS et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Oncol. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Kumar,. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al.